M&A Deal Summary |
|
|---|---|
| Date | 1988-01-01 |
| Target | Somerset Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) |
Viatris
Watson Pharmaceuticals |
| Deal Type | Joint Venture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1961 |
| Sector | Life Science |
| Employees | 32,000 |
| Revenue | 14.7B USD (2024) |
Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 14 |
| Sector: Life Science M&A | 1 of 11 |
| Type: Joint Venture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 2 |
| Country: United States M&A | 1 of 6 |
| Year: 1988 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-08-28 |
Mylan Laboratories
Secunderabad, India Mylan Laboratories Limited (Mylan Labs), a subsidiary of U.S.-based Mylan Inc. (Nasdaq: MYL), is one of the world’s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs). Based in Hyderabad, India, Mylan Labs offers more than 150 APIs and intermediates to customers in more than 80 countries across a wide range of therapeutic categories. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1931 |
| Sector | Medical Products |
| Employees | 1,325 |
Watson Pharmaceuticals, Inc.,is a specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 9 |
| Sector: Life Science M&A | 1 of 5 |
| Type: Joint Venture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 1988 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-01-22 |
Fiorinal and Fioricet product lines
United States The Fioricet(R) and Fiorinal(R) lines of products are indicated for the treatment of tension headaches. |
Buy | $178M |